StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc. (REGN) stock

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3010% above fair value
$952.40−3.07 (-0.32%)

Close on Nov 16, 2026Market cap $98.52BP/E 21.0Yield –

Regeneron Pharmaceuticals enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Regeneron Pharmaceuticals's enterprise value was $96.79B on Nov 11, 2026, against $79.48B a year earlier. Over the last 5 years it ranged from $49.58B to $127.70B, with a median of $77.29B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$96.79B+23.2%
2025Dec 31, 2025$78.56B+5.9%
2024Dec 31, 2024$74.18B-19.4%
2023Dec 29, 2023$92.06B+20.0%
2022Dec 30, 2022$76.72B+14.8%
2021Dec 31, 2021$66.81B+22.2%
2020Dec 31, 2020$54.65B+35.9%
2019Dec 31, 2019$40.22B-1.4%
2018Dec 31, 2018$40.77B-3.4%
2017Dec 29, 2017$42.21B+2.9%
2016Dec 30, 2016$41.03B-33.3%
2015Dec 31, 2015$61.50B+39.2%
2014Dec 31, 2014$44.20B+38.8%
2013Dec 31, 2013$31.85B+100.5%
2012Dec 31, 2012$15.89B+233.3%
2011Dec 30, 2011$4.77B+121.8%
2010Dec 31, 2010$2.15B–

More Regeneron Pharmaceuticals figures

See a number that looks wrong?